Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VTRS Viatris Inc.

休市中 03-14 16:00:00 EDT

9.10

+0.12

+1.34%

盘后9.10

+0.000.00%

19:58 EDT

最高9.12	最低8.98	成交量1,292万
今开9.00	昨收8.98	日振幅1.56%
总市值108.63亿	流通市值107.99亿	总股本11.94亿
成交额1.17亿	换手率1.09%	流通股本11.87亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VTRS","market":"US","secType":"STK","nameCN":"Viatris Inc.","latestPrice":9.1,"timestamp":1741982400000,"preClose":8.98,"halted":0,"volume":12922683,"hourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":9.1,"latestTime":"19:58 EDT","volume":1438097,"amount":13086624.7836,"timestamp":1741996694315},"delay":0,"floatShares":1186736347,"shares":1193688749,"eps":-0.531467,"marketStatus":"休市中","change":0.12,"latestTime":"03-14 16:00:00 EDT","open":9,"high":9.12,"low":8.98,"amount":117292964.857794,"amplitude":0.01559,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.531467,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1742198400000},"marketStatusCode":7,"adr":0,"listingDate":1605157200000,"exchange":"NASDAQ","adjPreClose":8.98,"dividendRate":0.052747,"preHourTrading":{"tag":"盘前","latestPrice":9,"preClose":8.98,"latestTime":"09:25 EDT","volume":3794,"amount":34261.918082,"timestamp":1741958700059},"postHourTrading":{"tag":"盘后","latestPrice":9.1,"preClose":9.1,"latestTime":"19:58 EDT","volume":1438097,"amount":13086624.7836,"timestamp":1741996694315},"volumeRatio":0.9007147095444817,"impliedVol":0.4139,"impliedVolPercentile":0.98},"requestUrl":"/m/hq/s/VTRS","defaultTab":"news","newsList":[{"id":"2517455736","title":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2517455736","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517455736?lang=zh_cn&edition=full","pubTime":"2025-03-08 01:22","pubTimestamp":1741368127,"startTime":"0","endTime":"0","summary":"杰富瑞投资银行：维持Viatris(VTRS.US)评级，由买入调整至买入评级, 目标价由15.00美元调整至13.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/08012248604905.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"gpt_icon":0},{"id":"2517167691","title":"晖致2024财年实现净利润-6.34亿美元，同比减少1259.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517167691","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517167691?lang=zh_cn&edition=full","pubTime":"2025-03-07 00:01","pubTimestamp":1741276870,"startTime":"0","endTime":"0","summary":"3月7日，晖致公布财报，公告显示公司2024财年净利润为-6.34亿美元，同比减少1259.05%；其中营业收入为147.10亿美元，同比减少4.37%，每股基本收益为-0.53美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307000136abeb8d1f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"2516658827","title":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516658827","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516658827?lang=zh_cn&edition=full","pubTime":"2025-03-01 07:04","pubTimestamp":1740783850,"startTime":"0","endTime":"0","summary":"巴克莱：维持Viatris(VTRS.US)评级，由减持调整至减持评级, 目标价由12.00美元调整至9.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01070448470449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VTRS"],"gpt_icon":0},{"id":"1105655803","title":"异动解读 | Viatris公司财报低于预期加上FDA限制措施 股价盘中暴跌20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1105655803","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1105655803?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:49","pubTimestamp":1740667786,"startTime":"0","endTime":"0","summary":"Viatris Inc.公司股价今日盘中暴跌20.73%,引发市场广泛关注。公司股价大幅走低的主要原因来自以下两个方面:. 首先,Viatris公司2024年第四季度的财报数据出现了不尽理想的表现。此外,早些时候美国FDA针对Viatris在印度印多尔的工厂实施进口限制措施,也给公司今年的业务发展带来了不利影响。Viatris预计FDA的行动将减少公司2025年的收入约5亿美元,调整后核心利润也将减少约3.85亿美元。监管部门措施加剧了市场对公司增长前景的担忧,进一步推动了股价的暴跌走势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"2514854013","title":"晖致盘中异动 股价大跌17.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514854013","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2514854013?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:30","pubTimestamp":1740666604,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时30分，晖致股票出现异动，股价快速下跌17.62%。截至发稿，该股报9.26美元/股，成交量222.466万股，换手率0.19%，振幅0.00%。晖致股票所在的制药行业中，整体涨幅为0.00%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722300498950f96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4583","BK4007","LU2087621335.USD","VTRS","LU1839511570.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"1139205945","title":"异动解读 | Viatris财报营收低于预期引发股价盘前大跌7.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139205945","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1139205945?lang=zh_cn&edition=full","pubTime":"2025-02-27 20:00","pubTimestamp":1740657635,"startTime":"0","endTime":"0","summary":"Viatris公司股价今日周四盘前交易大跌7.21%,主要受公司发布的2024年第四季度业绩报告拖累。\n\nViatris2024年第四季度财报显示,公司调整后每股收益0.54美元,低于市场预期的0.57美元;营收35.2亿美元,也未达到分析师预期的36.1亿美元。同时,财报显示公司同比去年的营收和每股收益均出现了下滑。\n\n公司业绩不达预期和同比下滑,令投资者对Viatris的盈利前景感到失望和担忧,引发了今日公司股票在盘前交易中大跌的行情。投资人将持续关注Viatris公司是否能在未来实现业绩复苏。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"1117219132","title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1117219132","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117219132?lang=zh_cn&edition=full","pubTime":"2025-02-27 19:58","pubTimestamp":1740657527,"startTime":"0","endTime":"0","summary":"Viatris  报告其季度每股收益为$0.54，比分析师一致预期的$0.57低5.26%。与去年同期的销售额$38.3亿相比，下降了8.13%。以上内容来自Benzinga Earnings专栏，原文如下：Viatris  reported quarterly earnings of $0.54 per share which missed the analyst consensus estimate of $0.57 by 5.26 percent. This is a 12.9 percent decrease over earnings of $0.62 per share from the same period last year.  The company reported quarterly sales of $3.52 billion which missed the analyst consensus estimate of $3.61 billion by 2.75 percent.  This is a 8.13 percent decrease over sa","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Viatris 2024年第四季度调整后每股收益$0.54低于预期$0.57，销售额$35.2亿低于预期$36.1亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":1},{"id":"2493700784","title":"Viatris doesn’t see FDA warning impacting current 2024 financial guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2493700784","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493700784?lang=zh_cn&edition=full","pubTime":"2024-12-24 19:55","pubTimestamp":1735041308,"startTime":"0","endTime":"0","summary":"06:51 EST Viatris (VTRS) doesn’t see FDA warning impacting current 2024 financial guidance Published first on TheFly – the ultimate source for real...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viatris-doesnt-see-fda-warning-impacting-current-2024-financial-guidance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Viatris认为FDA警告不会影响当前的2024年财务指引","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viatris-doesnt-see-fda-warning-impacting-current-2024-financial-guidance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4007","BK4583","LU2087621335.USD","LU1839511570.USD","BK4588","VTRS"],"gpt_icon":0},{"id":"2493007347","title":"Viatris confirms receipt of warning letter, import alert for India facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2493007347","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2493007347?lang=zh_cn&edition=full","pubTime":"2024-12-24 19:50","pubTimestamp":1735041008,"startTime":"0","endTime":"0","summary":"Viatris (VTRS) issued the following statement: “Our plants around the world are regularly inspected by health authorities to ensure compliance with...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/viatris-confirms-receipt-of-warning-letter-import-alert-for-india-facility?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"Viatris确认收到印度工厂的警告信和进口警报","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/viatris-confirms-receipt-of-warning-letter-import-alert-for-india-facility?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4583","BK4007","LU2087621335.USD","VTRS","LU1839511570.USD","BK4585","BK4588"],"gpt_icon":0},{"id":"2492950859","title":"Analysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Airsculpt Technologies, Inc. (AIRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492950859","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2492950859?lang=zh_cn&edition=full","pubTime":"2024-12-17 21:50","pubTimestamp":1734443422,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Viatris (VTRS – Research Report) and Airsculpt Tec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-and-airsculpt-technologies-inc-airs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"分析师提供对医疗保健公司的见解：Viatris(VTRS)和Airsculpt Technologies,Inc.(AIRS)","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-viatris-vtrs-and-airsculpt-technologies-inc-airs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","BK4585","LU2087621335.USD","BK4588","BK4137","BK4583","LU1839511570.USD","BK4007","VTRS","AIRS","BK4196"],"gpt_icon":0},{"id":"2485700255","title":"Viatris fined £1.5M for failure to comply with CMA order","url":"https://stock-news.laohu8.com/highlight/detail?id=2485700255","media":"seekingalpha","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2485700255?lang=zh_cn&edition=full","pubTime":"2024-11-22 19:26","pubTimestamp":1732274818,"startTime":"0","endTime":"0","summary":"Frank Brennan/iStock via Getty Images  Generic drugmaker Viatris  has been 1.5M by the U.K.'s Competition and Markets Authority  for failing to comply with compulsory restrictions imposed during the regulator’s review of its deal with Theramex. In Oct. 2023, Viatris  agreed to divest its rights to women’s health products, Duphaston and Femoston, to Theramex. Duphaston and Femoston, which comprise progesterone and estrogen receptor agonists, are prescribed as hormone replacement therapy  to help relieve menopause symptoms. Following a Phase 1 probe, in April 2024, the CMA said the deal would likely hurt competition in the HRT market. The antitrust regulator imposed an ‘Initial Enforcement Order’ which sought to prevent any action which could prejudice its inquiry or any potential remedies that the CMA might impose. The regulator said Viatris  breached these restrictions by implementing changes to key members of its UK management team without the CMA’s consent, and then failed to notify ","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142910891/image_2142910891.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2142910891/image_2142910891.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"Viatris因未能遵守CMA命令而被罚款150万英镑","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4320334-viatris-fined-15m-for-failure-to-comply-with-cma-order","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["BK4589","CMA","BK4583","BK4007","BK4130","BK4585","BK4207","HRT","LU2087621335.USD","VTRS","LU1839511570.USD","BK4588","BK4211"],"gpt_icon":0},{"id":"2484102005","title":"晖致2024财年第三财季实现净利润94.80百万美元，同比减少71.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484102005","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484102005?lang=zh_cn&edition=full","pubTime":"2024-11-17 00:01","pubTimestamp":1731772898,"startTime":"0","endTime":"0","summary":"11月17日，晖致公布财报，公告显示公司2024财年第三财季净利润为94.80百万美元，同比减少71.45%；其中营业收入为37.57亿美元，同比减少4.30%，每股基本收益为0.08美元。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241117000235abc78f6b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VTRS"],"gpt_icon":0},{"id":"1156794825","title":"Stock Track | Viatris Stock Soars 15% as Q3 Results Beat Estimates on Strong New Drug Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=1156794825","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156794825?lang=zh_cn&edition=full","pubTime":"2024-11-08 12:40","pubTimestamp":1731040851,"startTime":"0","endTime":"0","summary":"Shares of Viatris Inc.  soared 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by robust demand for its newly launched generic drugs.For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, slightly ahead of the consensus forecast of $3.71 billion.The company's impressive performance was driven by str","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"股票轨迹Viatris股价飙升15%，第三季度业绩超出预期，新药销售强劲","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VTRS"],"gpt_icon":0},{"id":"1184610928","title":"Stock Track | Viatris Stock Soars as Q3 Results Beat Estimates on Robust New Drug Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1184610928","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1184610928?lang=zh_cn&edition=full","pubTime":"2024-11-08 05:40","pubTimestamp":1731015651,"startTime":"0","endTime":"0","summary":"Shares of Viatris Inc.  surged a staggering 15.68% on November 7, 2024, after the generic drugmaker reported better-than-expected third-quarter results, fueled by strong demand for its newly launched generic drugs.For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.74 billion, beating the consensus forecast of $3.71 billion.\"We continue to make excellent progress executing o","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"由于新药需求强劲，第三季度业绩超出预期，Viatris股价飙升","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VTRS"],"gpt_icon":0},{"id":"2481913921","title":"Generic Drugmaker Viatris Beats Expectations In Q3, CEO Praises $2 Billion Debt Paydown","url":"https://stock-news.laohu8.com/highlight/detail?id=2481913921","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481913921?lang=zh_cn&edition=full","pubTime":"2024-11-08 01:39","pubTimestamp":1731001170,"startTime":"0","endTime":"0","summary":"Viatris reports Q3 2024 net sales of $3.74 billion, beating estimates. Adjusted EPS at $0.75 surpasses $0.68 consensus. 2024 guidance reaffirms strong growth outlook.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"仿制药制造商Viatris第三季度超出预期，首席执行官赞扬20亿美元债务偿还","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41817764/generic-drugmaker-viatris-beats-expectations-in-q3-ceo-praises-2-billion-debt-paydown","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2087621335.USD","VTRS","BK4588","LU1839511570.USD","BK4583","BK4007","BK4585"],"gpt_icon":0},{"id":"2481144180","title":"Viatris nears 11-month high after Q3 beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2481144180","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481144180?lang=zh_cn&edition=full","pubTime":"2024-11-07 23:42","pubTimestamp":1730994134,"startTime":"0","endTime":"0","summary":"filoViatris (NASDAQ:VTRS) shares reached the highest level since late February on Thursday after the maker of the anxiety drug Xanax reported better-than-expected financials for Q3 2024 and set its revenue outlook ahead of consensus. The Pennsylvania-based drugmaker, which formed in 2020","market":"other","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975508657/image_1975508657.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1975508657/image_1975508657.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"Viatris在第三季度表现出色后接近11个月高点","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4261515-viatris-stock-jumps-after-q-3-beat","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":[".IXIC","MNQmain","NQmain","SQQQ","PSQ","QID","QLD","VTRS","BK4007","BK4585","BK4588","LU1839511570.USD","LU2087621335.USD","TQQQ","BK4583"],"gpt_icon":0},{"id":"1191066803","title":"Stock Track | Viatris Stock Soars 5% as Q3 Results Beat Estimates on New Drug Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=1191066803","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191066803?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:50","pubTimestamp":1730991039,"startTime":"0","endTime":"0","summary":"Shares of Viatris Inc.  surged over 5% on Wednesday after the generic drugmaker reported better-than-expected third-quarter results, driven by strong demand for its newly launched generic drugs.For the quarter ended September 30, 2024, Viatris posted adjusted earnings of $0.75 per share, surpassing analysts' average estimate of $0.68 per share. Revenue came in at $3.8 billion, slightly ahead of the consensus forecast of $3.71 billion.The company's performance was boosted by robust sales of its r","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"股票轨迹Viatris股价飙升5%，第三季度业绩超出新药需求预期","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["VTRS"],"gpt_icon":0},{"id":"1142747545","title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1142747545","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1142747545?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:48","pubTimestamp":1730990923,"startTime":"0","endTime":"0","summary":"制药公司Viatris股价在11月7日盘中大涨5.08%,引发市场关注。公司新鲜出炉的第三季度财报成为推动股价上涨的主因。数据显示,Viatris第三季度营收达37.4亿美元,超过分析师预期的37.1亿美元。Viatris是2020年由默克和辉瑞旗下业务合并组建而成,在品牌药和仿制药两大领域都有版图。除了新产品销售亮眼,公司传统品牌药如伟哥、Xanax等也保持了稳健增长。本季度,其品牌药业务同比增长2%至23.6亿美元,仿制药业务增长4%至13.8亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 新药亮眼业绩超预期 Viatris股价大涨5%","news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["VTRS"],"gpt_icon":0},{"id":"2481890071","title":"晖致盘中异动 早盘快速上涨5.00%报12.19美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2481890071","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481890071?lang=zh_cn&edition=full","pubTime":"2024-11-07 22:33","pubTimestamp":1730990034,"startTime":"0","endTime":"0","summary":"北京时间2024年11月07日22时33分，晖致股票出现异动，股价快速拉升5.00%。截至发稿，该股报12.19美元/股，成交量53.4534万股，换手率0.04%，振幅3.88%。晖致股票所在的制药行业中，整体涨幅为0.63%。通过强强联手，晖致医药有限公司成为世界上最大的仿制药制造商之一，为超过 165 个国家提供服务。虽然涵盖 10 多个主要治疗领域，但晖致医药有限公司已将皮肤科、眼科和胃肠科确定为未来创新的三个关键重点领域。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024110722335498e4131a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2087621335.USD","BK4585","BK4583","VTRS","LU1839511570.USD","BK4588","BK4007"],"gpt_icon":0},{"id":"2481903628","title":"Viatris Q3 2024 Adj. EPS $0.75 Beats $0.68 Estimate, Sales $3.740B Beat $3.709B Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2481903628","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2481903628?lang=zh_cn&edition=full","pubTime":"2024-11-07 20:12","pubTimestamp":1730981542,"startTime":"0","endTime":"0","summary":"Viatris (NASDAQ:VTRS) reported quarterly earnings of $0.75 per share which beat the analyst consensus estimate of $0.68 by 10.29 percent. This is a 5.06 percent decrease over earnings of $0.79 per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"Viatris 2024年第三季度调整后。EPS$0.75超出预期$0.68，销售额$3.740 B超出预期$3.709 B","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41803241/viatris-q3-2024-adj-eps-0-75-beats-0-68-estimate-sales-3-740b-beat-3-709b-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Viatris Q3 2024 Adj. EPS $0.75 Beats $0.68 Estimate, Sales $3.740B Beat $3.709B Estimate","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VTRS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.viatris.com","stockEarnings":[{"period":"1week","weight":-0.057},{"period":"1month","weight":-0.1415},{"period":"3month","weight":-0.2795},{"period":"6month","weight":-0.2196},{"period":"1year","weight":-0.2301},{"period":"ytd","weight":-0.2691}],"compareEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":-0.0672},{"period":"3month","weight":-0.0685},{"period":"6month","weight":0.0014},{"period":"1year","weight":0.0929},{"period":"ytd","weight":-0.0397}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Viatris Inc.于2019年2月14日在特拉华州成立。该公司是一家全球性的医疗保健公司，该公司认为他们具有独特的定位，可以弥合仿制药和品牌之间的传统鸿沟，将两者的优点结合起来，以更全面地满足全球范围内的医疗保健需求。Viatris的使命是赋能世界各地的人们在生命的每个阶段都能过上更健康的生活，大规模地提供准入服务，目前每年为全球约10亿患者提供高质量的药物，并触及生命的所有时刻，从出生到生命的尽头，从急性病到慢性病。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.019682},{"month":2,"riseRate":0.2,"avgChangeRate":-0.116749},{"month":3,"riseRate":0,"avgChangeRate":-0.05521},{"month":4,"riseRate":0,"avgChangeRate":-0.039911},{"month":5,"riseRate":0.5,"avgChangeRate":0.057634},{"month":6,"riseRate":0.5,"avgChangeRate":-0.028874},{"month":7,"riseRate":0.5,"avgChangeRate":0.024935},{"month":8,"riseRate":0.75,"avgChangeRate":0.011976},{"month":9,"riseRate":0,"avgChangeRate":-0.075843},{"month":10,"riseRate":0.25,"avgChangeRate":0.018996},{"month":11,"riseRate":0.75,"avgChangeRate":0.042713},{"month":12,"riseRate":0.8,"avgChangeRate":0.070634}],"exchange":"NASDAQ","name":"Viatris Inc.","nameEN":"Viatris Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.7","shortVersion":"4.31.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Viatris Inc.,VTRS,Viatris Inc.股票,Viatris Inc.股票老虎,Viatris Inc.股票老虎国际,Viatris Inc.行情,Viatris Inc.股票行情,Viatris Inc.股价,Viatris Inc.股市,Viatris Inc.股票价格,Viatris Inc.股票交易,Viatris Inc.股票购买,Viatris Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Viatris Inc.(VTRS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Viatris Inc.(VTRS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}